期刊文献+

ABCG2基因多态性与结直肠癌发生发展的相关性研究

Study on the correlation between the polymorphism of ABCG2 gene and the occurrence and progression of colorectal cancer
原文传递
导出
摘要 目的探讨ABCG2基因rs2231137和rs2231142单核苷酸多态性(SNP)与结直肠癌发生发展的关系。方法选取2016年1月至2017年7月采用病例-对照研究,收集结直肠癌患者外周血样本690份,社区健康体检者外周血样本431份,使用TaqMan实时荧光定量PCR方法进行基因分型,应用χ~2检验和logistic回归进行ABCG2 rs2231137和rs2231142基因多态性与结直肠癌关联分析。结果对性别和年龄进行分层分析显示,携带ABCG2 rs2231142 AA基因型的男性,与CC基因型相比,结直肠癌发病风险降低(OR=0.50,95%CI:0.28~0.90,P=0.022)。年龄≤60岁携带rs2231137 AA基因型的结直肠癌患者发生Ⅰ、Ⅱ期肿瘤的比例高于Ⅲ、Ⅳ期(OR=0.29,95%CI:0.14~0.61,P=0.001)。结论 ABCG2 rs2231137和rs2231142单核苷酸多态性与结直肠癌的发生发展相关。 Objective The aim of the present study was to explore the correlation between the single nucleotide polymorphisms(SNP) of ABCG2 gene rs2231137 and rs2231142 and the occurrence and progression of colorectal cancer. Methods From January 2016 to July 2017, a case-control study was conducted to collect 690 peripheral blood samples from patients with colorectal cancer, and 431 peripheral blood samples from community healthy individuals.TaqMan real-time fluorescence quantitative PCR was used for genotyping.Chi-square test and logistic regression were used to analyze the association of ABCG2 rs2231137 and rs2231142 gene polymorphism with colorectal cancer. Results By stratified analysis of sex and age, it showed that men with the ABCG2 rs2231142 AA genotype had lower risk of colorectal cancer compared with the CC genotype(OR=0.50, 95%CI:0.28-0.90, P=0.022).The percentage of patients with stage Ⅰ and stage Ⅱ tumors was 0.293 times higher than those with stage Ⅲ and Ⅳ tumors among patients aged 60 years and older who carried rs2231137 AA genotype, suggesting a slower progression of tumor in those patients(OR=0.29, 95%CI:0.14-0.61, P=0.001). Conclusions Single nucleotide polymorphisms of rs2231137 and rs2231142 in ABCG2 gene were associated with the occurrence and development of colorectal cancer.
作者 张晓梅 孔晓玲 洪伟伟 张琰 武渊 程艳萍 杨圣 许思易 刘桐 梁戈玉 沈波 ZHANG Xiao-mei;KONG Xiao-ling;HONG Wei-wei;ZHANG Yan;WU Yuan;CHENG Yan-ping;YANG Sheng;XU Si-yi;LIU Tong;LIANG Ge-yu;SHEN Bo(Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Nanjing Medical University Affiliated Cancer Hospital,Nanjing,Jiangsu 210009,China)
出处 《中国预防医学杂志》 CAS CSCD 2019年第4期265-270,共6页 Chinese Preventive Medicine
基金 国家自然科学基金资助项目(81673132) 江苏省科技项目(BE2015719)
关键词 转运蛋白 ABCG2 单核苷酸多态性 结直肠癌 连锁不平衡 Transporter ABCG2 Single nucleotide polymorphism Colorectal cancer Linkage disequilibrium
  • 相关文献

参考文献4

二级参考文献59

  • 1Ling Yang.Incidence and mortality of gastric cancer in China[J].World Journal of Gastroenterology,2006,12(1):17-20. 被引量:345
  • 2陈明立,谭远发.我国东中西部三大区域人口竞争力实证比较研究[J].经济学家,2007(2):53-63. 被引量:6
  • 3JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J].CA Cancer J CUn, 201 1, 61(2):69-90.
  • 4TOURNIGAND C, ANDRE T, ACHILLE E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized CERCOR study[J].JClin Oncol, 2004, 22(2):229-237.
  • 5COLUCCI G, GEBBIA V, PAOLETTI G,et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Cruppo Oncologico Dell,Italia Meridionale[J].J Clin Oncol, 2005, 23(22):4866-4875.
  • 6DUCREUX M, BENNOUNA J, HEBBAR M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer[J]. Int J Cancer, 2011, 128(3):682-690.
  • 7ENCSTROM P F, ARNOLETTI J P,BENSON A R, et aL NCCN Clinical Practice Guidelines in Oncology: colon cancer[J]. J Natl Compr Cane Neter 2009, 7(8):778-831.
  • 8Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. AdvancedColorectal Cancer Meta-Analysis Project[J].J ClinOncol, 1992, 10(6):896-903.
  • 9VAN CUTSEM E, HOFF P M,HARPER P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials[J].BrJ Cancer, 2004, 90(6):11 90-1197.
  • 10HOFF P M,ANSARI R,BATIST G, ef al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study[J].J Clin Oncol, 2001,19(8):2282-2292.

共引文献1147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部